how genetic variations and drug interactions may decrease the efficacy of clopidogrel (Plavix)
July 2009
New labeling will focus on how genetic variations and drug interactions may decrease the efficacy of clopidogrel (Plavix).
These factors can lead to less efficient CYP2C19 metabolism...one of the main enzymes that converts clopidogrel to its active form.
Genetics. About 30% of whites and blacks and over 50% of Asians have variations that decrease clopidogrel metabolism. This might translate to a higher risk for cardiac events.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote